18452059. HUNTINGTIN MIMETIC PROTEIN-LIKE POLYMERS AND USES THEREOF simplified abstract (THE REGENTS OF THE UNIVERSITY OF CALIFORNIA)
Contents
- 1 HUNTINGTIN MIMETIC PROTEIN-LIKE POLYMERS AND USES THEREOF
- 1.1 Organization Name
- 1.2 Inventor(s)
- 1.3 HUNTINGTIN MIMETIC PROTEIN-LIKE POLYMERS AND USES THEREOF - A simplified explanation of the abstract
- 1.4 Simplified Explanation
- 1.5 Potential Applications
- 1.6 Problems Solved
- 1.7 Benefits
- 1.8 Potential Commercial Applications
- 1.9 Possible Prior Art
- 1.10 Original Abstract Submitted
HUNTINGTIN MIMETIC PROTEIN-LIKE POLYMERS AND USES THEREOF
Organization Name
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Inventor(s)
Nathan C. Gianneschi of Wilmette IL (US)
Mara A. Fattah of Evanston IL (US)
Wonmin Choi of Evanston IL (US)
HUNTINGTIN MIMETIC PROTEIN-LIKE POLYMERS AND USES THEREOF - A simplified explanation of the abstract
This abstract first appeared for US patent application 18452059 titled 'HUNTINGTIN MIMETIC PROTEIN-LIKE POLYMERS AND USES THEREOF
Simplified Explanation
The patent application discloses protein-like polymers that can inhibit the protein-protein interaction between VCP and mutant-type Huntingtin protein.
- The protein-like polymers are composed of a polymer of formula (FX1) or (FX2).
- These polymers have the ability to disrupt the interaction between VCP and mutant-type Huntingtin protein.
Potential Applications
The technology could potentially be applied in the development of therapies for Huntington's disease or other protein misfolding disorders.
Problems Solved
This technology addresses the issue of protein-protein interactions that contribute to the progression of diseases like Huntington's.
Benefits
The protein-like polymers offer a novel approach to targeting specific protein interactions, potentially leading to more effective treatments for related diseases.
Potential Commercial Applications
- "Protein-like Polymers for Huntington's Disease Therapy" - Optimized for SEO
Possible Prior Art
There may be prior art related to the development of protein-like polymers for disrupting protein-protein interactions in various diseases.
What are the specific chemical structures of the protein-like polymers mentioned in the patent application?
The specific chemical structures of the protein-like polymers are represented by the formulas (FX1) and (FX2).
How do the protein-like polymers inhibit the protein-protein interaction between VCP and mutant-type Huntingtin protein at a molecular level?
The protein-like polymers disrupt the interaction between VCP and mutant-type Huntingtin protein by binding to specific regions on the proteins, preventing them from interacting with each other.
Original Abstract Submitted
Disclosed are protein-like polymers and uses thereof. The protein-like polymers generally comprise a polymer of formula (FX1) or (FX2). The polymer of formula (FX1) or (FX2) in some aspects inhibits the protein-protein interaction between VCP and mutant-type Huntingtin protein.
